Bristol Glucophage Phase IV protocol release could impede study, Bristol asserts in case brought by HRG.
BRISTOL GLUCOPHAGE PHASE IV PROTOCOL RELEASE COULD DISRUPT STUDY, ATTORNEY Michael Petty (Fox, Bennett & Turner) asserted on behalf of Bristol-Myers Squibb during a Jan. 27 hearing in D.C. federal court. The hearing was held to consider summary judgment requests in a case brought against FDA by Public Citizen's Health Research Group seeking release of Bristol's protocol for a 10,000-patient study of the oral antidiabetic Glucophage (metformin) under the Freedom of Information Act. Bristol intervened in the suit as a defendant.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth